已上市胰高血糖素样肽-1受体激动剂的研究进展

胰高血糖素样肽-1受体激动剂（GLP-1RAs）治疗2型糖尿病受到广泛关注，其不仅具有优异的降糖优势，还有控制体质量，调节血脂，改善胰岛β细胞功能等特点，同时低血糖或体质量增加的不良反应发生率较低。自2005年至今，已经有7个GLP-1RAs经美国食品药品监督管理局批准上市，即艾塞那肽、利拉鲁肽、艾塞那肽长效制剂、阿必鲁肽、度拉糖肽、利西拉来和索马鲁肽；在中国上市的有贝那鲁肽和洛塞那肽。对已经上市的9个GLP-1Ras治疗2型糖尿病的临床研究进展进行综述。

Research progress on glucagon-like peptide-1 receptor agonists on market

Glucagon-like peptide-1 receptor agonists(GLP-1RAs)are widely used in the treatment of type 2 diabetes mellitus. GLP- 1RAs not only has the advantages of reducing blood glucose, but also has the characteristics of controlling body mass, regulating blood lipid, improving the function of islet beta cells.At the same time, the incidence of adverse reactions caused by hypoglycemia or increased body mass is relatively low. Since 2005, seven GLP-1RAs have been approved by the U. S. Food and Drug Administration for listing, i. e. exenatide, liraglutide, exenatide long-acting preparation, albiglutide, dulaglutide, lixisenatide and semaglutide; beinaglutide and loxenatide are listed in China. The clinical research progress of nine GLP-1RAs in the treatment of type 2 diabetes was reviewed.